Table 2 Univariable and multivariable logistic and Cox regression analyses of risk factors associated with RR, PFS, and OS
RR* | PFS# | OS$ | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis | |||||||
OR (95% CI) | p-value | OR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | |
Heng Prognostic Score | ||||||||||||
Low | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
Int/High^ | 0.500 (0.124,1.973) | 0.319 | 0.553 (0.130,2.322) | 0.414 | 0.779 (0.379,1.6) | 0.496 | 0.892 (0.433,1.837) | 0.757 | 0.514 (0.182,1.451) | 0.201 | 0.559 (0.197,1.585) | 0.274 |
Duration of prior anti-VEGF Therapies | ||||||||||||
< 6 Months | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
≥ 6 Months | 2.200 (0.613,8.678) | 0.237 | 2.362 (0.627,9.979) | 0.216 | 2.015 (1.046,3.883) | 0.048 | 2.288 (1.094,4.785) | 0.028 | 2.869 (0.9,9.141) | 0.063 | 2.913 (0.904,9.388) | 0.073 |
Pretherapy NLR | ||||||||||||
< 3 | Reference | Reference | Reference | Reference | Reference | Reference | ||||||
≥ 3 | 2.567 (0.717,10.16) | 0.158 | 2.538 (0.674,10.57) | 0.178 | 2.67 (1.343,5.308) | 0.004 | 2.937 (1.444,5.972) | 0.003 | 3.977 (1.227,12.889) | 0.014 | 4.01 (1.189,13.524) | 0.025 |